Vaxart Inc (OQ:VXRT)
Business Focus: Bio Therapeutic Drugs
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 170 Harbor Way, Suite 300 SOUTH SAN FRANCISCO CA 94080 |
| Tel: | N/A |
| Website: | https://vaxart.com |
| IR: | See website |
| Key People | ||
| Michael J. Finney Chairman of the Board | Steven Lo President, Chief Executive Officer, Director | Phillip E. Lee Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer |
| Sean N. Tucker Senior Vice President, Chief Scientific Officer | Edward B. Berg Senior Vice President, General Counsel | Raymond D. Stapleton Chief Technology Officer | James F. Cummings Chief Medical Officer |
| Business Overview |
| Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Vaxart Inc revenues increased from $107K to $7.4M. Net loss decreased 23% to $82.5M. Revenues reflect Royalty Income - Business increase from $107K to $3.9M. Lower net loss reflects Research and development - Balancing decrease of 17% to $59.8M (expense), General and administrative - Balancing decrease of 33% to $16.8M (expense), Impairment of intangible assets decrease from $4.3M (expense) to $0K. |
| Employees: | 109 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $91.38M as of Dec 31, 2023 |
| Annual revenue (TTM): | $7.38M as of Dec 31, 2023 |
| EBITDA (TTM): | -$74.72M as of Dec 31, 2023 |
| Net annual income (TTM): | -$82.47M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$72.32M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 176,838,011 as of Apr 12, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.